IDH1 and cancer: This could likely be attributed to the IDH1 missense variant as seen in Figure 5E. On the other hand, the fibroblast growth factor receptor (FGFR) inhibitor, infigratinib, exhibited a marginal inhibitory effect on the cancer organoid.